CO2017003969A2 - Derivado de isoxazol como inhibidor de isocitrato deshidrogenasa 1 mutante - Google Patents
Derivado de isoxazol como inhibidor de isocitrato deshidrogenasa 1 mutanteInfo
- Publication number
- CO2017003969A2 CO2017003969A2 CONC2017/0003969A CO2017003969A CO2017003969A2 CO 2017003969 A2 CO2017003969 A2 CO 2017003969A2 CO 2017003969 A CO2017003969 A CO 2017003969A CO 2017003969 A2 CO2017003969 A2 CO 2017003969A2
- Authority
- CO
- Colombia
- Prior art keywords
- inhibitor
- isocitrate dehydrogenase
- isoxazole derivative
- mutant isocitrate
- protein
- Prior art date
Links
- 229940123392 Isocitrate dehydrogenase 1 inhibitor Drugs 0.000 title 1
- 150000002545 isoxazoles Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 101001042041 Bos taurus Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial Proteins 0.000 abstract 1
- 101000960234 Homo sapiens Isocitrate dehydrogenase [NADP] cytoplasmic Proteins 0.000 abstract 1
- 102100039905 Isocitrate dehydrogenase [NADP] cytoplasmic Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 125000000842 isoxazolyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se ha encontrado que un compuesto de la fórmula general (I) que tiene una estructura de isoxazol tiene excelente actividad inhibidora contra la proteína IDH1 mutante e inhibe la producción de 2-HG por esta proteína, mientras que el compuesto también es capaz de inhibir efectivamente el crecimiento de varios tumores que expresan la proteína. En la fórmula, R1, R2, R3, Y y Z son como se definen en la reivindicación 1.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014203475 | 2014-10-01 | ||
JP2015116774 | 2015-06-09 | ||
PCT/JP2015/077916 WO2016052697A1 (ja) | 2014-10-01 | 2015-10-01 | 変異型イソクエン酸デヒドロゲナーゼ1阻害剤としてのイソキサゾール誘導体 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2017003969A2 true CO2017003969A2 (es) | 2017-07-11 |
Family
ID=55630718
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2017/0003969A CO2017003969A2 (es) | 2014-10-01 | 2017-04-24 | Derivado de isoxazol como inhibidor de isocitrato deshidrogenasa 1 mutante |
Country Status (26)
Country | Link |
---|---|
US (1) | US10040791B2 (es) |
EP (1) | EP3202766B1 (es) |
JP (1) | JP6087033B2 (es) |
KR (1) | KR102440429B1 (es) |
CN (1) | CN106795146B (es) |
AU (1) | AU2015325279B2 (es) |
BR (1) | BR112017006425B8 (es) |
CA (1) | CA2963359C (es) |
CO (1) | CO2017003969A2 (es) |
CY (1) | CY1122891T1 (es) |
DK (1) | DK3202766T3 (es) |
ES (1) | ES2779305T3 (es) |
HR (1) | HRP20200395T1 (es) |
HU (1) | HUE048997T2 (es) |
IL (1) | IL251305B (es) |
LT (1) | LT3202766T (es) |
MX (1) | MX2017003782A (es) |
PH (1) | PH12017500530B1 (es) |
PL (1) | PL3202766T3 (es) |
PT (1) | PT3202766T (es) |
RS (1) | RS60064B1 (es) |
RU (1) | RU2692782C2 (es) |
SG (1) | SG11201702389XA (es) |
SI (1) | SI3202766T1 (es) |
WO (1) | WO2016052697A1 (es) |
ZA (1) | ZA201703013B (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10253041B2 (en) * | 2015-07-27 | 2019-04-09 | Eli Lilly And Company | 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds and their use as mutant IDH1 inhibitors |
EP3464281B1 (en) | 2016-06-06 | 2020-07-08 | Eli Lilly and Company | Mutant idh1 inhibitors |
WO2018010142A1 (en) * | 2016-07-14 | 2018-01-18 | Shanghai Meton Pharmaceutical Co., Ltd | Iso-citrate dehydrogenase (idh) inhibitor |
WO2019025256A1 (en) * | 2017-08-01 | 2019-02-07 | Bayer Aktiengesellschaft | COMBINATION OF MIDH1 INHIBITORS AND DNA HYPOMETHYLATION (AHM) AGENTS |
MX2018002612A (es) * | 2018-01-29 | 2019-07-30 | Fujifilm Corp | Composicion farmaceutica para tumor que tiene mutacion de isocitrato deshidrogenada, agente antitumoral y uso del mismo. |
WO2021176098A1 (en) | 2020-03-05 | 2021-09-10 | Université de Lausanne | Modulators of aralar for treating neurological disorders |
AU2021311539A1 (en) | 2020-07-21 | 2023-02-09 | Daiichi Sankyo Company, Limited | Combination drug of temozolomide and inhibitor of mutated IDH1 enzyme |
AU2021371592A1 (en) * | 2020-10-30 | 2023-06-15 | Daiichi Sankyo Company, Limited | Method of producing 3-methyl-4-halo-indole derivative |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3194811A (en) | 1963-09-05 | 1965-07-13 | Merck & Co Inc | Aroyl-benzindolyl acids |
WO1994010145A1 (en) | 1992-10-23 | 1994-05-11 | Merck Sharp & Dohme Limited | Dopamine receptor subtype ligands |
WO1994024095A1 (en) | 1993-04-16 | 1994-10-27 | Abbott Laboratories | Immunosuppressive agents |
GB2284600A (en) * | 1994-01-21 | 1995-06-14 | Shell Int Research | Herbicidal 3-(hetero)aryl-4-acylisoxazole compositions and compounds |
JP4921162B2 (ja) | 2003-02-11 | 2012-04-25 | ヴァーナリス(ケンブリッジ)リミテッド | 熱ショックタンパク質の阻害剤としてのイソオキサゾール化合物類 |
RU2392273C2 (ru) * | 2004-09-10 | 2010-06-20 | Синджента Лимитед | Замещенные изоксазолы в качестве фунгицидов |
WO2012009678A1 (en) * | 2010-07-16 | 2012-01-19 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their method of use |
WO2012173682A2 (en) | 2011-03-29 | 2012-12-20 | The Broad Institute, Inc. | Compounds and methods for the treatment of isocitrate dehydrognase related diseases |
CN102827073A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
CN102827170A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
CA2849995A1 (en) | 2011-09-27 | 2013-04-04 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
WO2013107405A1 (en) | 2012-01-19 | 2013-07-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
US9474779B2 (en) | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
-
2015
- 2015-10-01 BR BR112017006425A patent/BR112017006425B8/pt active IP Right Grant
- 2015-10-01 KR KR1020177011877A patent/KR102440429B1/ko active IP Right Grant
- 2015-10-01 DK DK15845549.3T patent/DK3202766T3/da active
- 2015-10-01 SG SG11201702389XA patent/SG11201702389XA/en unknown
- 2015-10-01 PT PT158455493T patent/PT3202766T/pt unknown
- 2015-10-01 HU HUE15845549A patent/HUE048997T2/hu unknown
- 2015-10-01 RS RS20200290A patent/RS60064B1/sr unknown
- 2015-10-01 AU AU2015325279A patent/AU2015325279B2/en active Active
- 2015-10-01 CN CN201580050809.8A patent/CN106795146B/zh active Active
- 2015-10-01 LT LTEP15845549.3T patent/LT3202766T/lt unknown
- 2015-10-01 WO PCT/JP2015/077916 patent/WO2016052697A1/ja active Application Filing
- 2015-10-01 CA CA2963359A patent/CA2963359C/en active Active
- 2015-10-01 SI SI201531109T patent/SI3202766T1/sl unknown
- 2015-10-01 PL PL15845549T patent/PL3202766T3/pl unknown
- 2015-10-01 US US15/516,362 patent/US10040791B2/en active Active
- 2015-10-01 JP JP2016552161A patent/JP6087033B2/ja active Active
- 2015-10-01 RU RU2017114005A patent/RU2692782C2/ru active
- 2015-10-01 ES ES15845549T patent/ES2779305T3/es active Active
- 2015-10-01 EP EP15845549.3A patent/EP3202766B1/en active Active
- 2015-10-01 MX MX2017003782A patent/MX2017003782A/es unknown
-
2017
- 2017-03-21 IL IL251305A patent/IL251305B/en active IP Right Grant
- 2017-03-22 PH PH12017500530A patent/PH12017500530B1/en unknown
- 2017-04-24 CO CONC2017/0003969A patent/CO2017003969A2/es unknown
- 2017-04-28 ZA ZA2017/03013A patent/ZA201703013B/en unknown
-
2020
- 2020-03-10 HR HRP20200395TT patent/HRP20200395T1/hr unknown
- 2020-03-13 CY CY20201100221T patent/CY1122891T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2017003969A2 (es) | Derivado de isoxazol como inhibidor de isocitrato deshidrogenasa 1 mutante | |
CU24410B1 (es) | Benzimidazol-2-aminas como inhibidores de midh1 | |
CU24411B1 (es) | Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos | |
CR20150509A (es) | Derivados de naftiridina utiles como antagonistas de la alfa-v-beta-6 integrina | |
CR20150491A (es) | 3-pirimidin-4-il oxazolidin -2- onas como inhibidores de idh mutante | |
AU2015374458A8 (en) | Use of picolinamide compounds with fungicidal activity | |
GT201500348A (es) | Compuestos de pirimidinodiona contra estados cardíacos | |
CL2017001650A1 (es) | Derivados de 5-[(piperazina-1-yl)-3-oxo-propilo]-imidazolidina-2,4-dionan como inhibidores adamts para el tratamiento oesteoartritis. | |
CL2018000070A1 (es) | Modulares de diaciglicerol aciltransderasa 2 (dgta2) | |
PE20180024A1 (es) | Triazolopirazinonas como inhibidores de pde1 | |
EA201692219A1 (ru) | Способы получения противовирусных соединений | |
EA201600589A1 (ru) | Ингибиторы диацилглицеринацилтрансферазы 2 для применения в лечении метаболических и связанных с метаболизмом расстройств | |
AR098274A1 (es) | Inhibidor de grelina o-acil transferasa | |
ECSP13013038A (es) | Inhibidores sustituidos de acetil-coa carboxilasa | |
AU2017317563A8 (en) | Detergent compositions comprising xanthan lyase variants I | |
EA201792021A1 (ru) | Ингибитор jak | |
TR201905233T4 (tr) | Dirençli bakteriyel enfeksiyonların tedavisine yönelik kombinasyon tedavisi. | |
BR112017008176A2 (pt) | método de preparação do carbonato de ácido glicérico. | |
GT201500247A (es) | Imidazopiridazinas sustituidas | |
SG10201805896SA (en) | PPARγ AGONISTS FOR TREATMENT OF MULTIPLE SCLEROSIS | |
EA201691412A1 (ru) | Гидроксиформамидные производные и их применение | |
CY1122506T1 (el) | Κρυσταλλικη μορφη της ενωσης (s)-3-{4-[5-(2-κυκλοπεντυλ-6- μεθοξυ- πυριδιν-4- υλ)-[1,2,4]οξαδιαζολ-3- υλ]-2- αιθυλ-6-μεθυλ- φαινοξυ}- προπανο-1,2- διολη | |
EA201791530A1 (ru) | НОВЫЕ N-АЦИЛАРИЛСУЛЬФОНАМИДНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ АМИНОАЦИЛ-тРНК СИНТЕТАЗЫ | |
EA201690227A1 (ru) | Азаиндольные соединения, их получение и способы их применения | |
EA201791645A1 (ru) | Новые соли и полиморфы scy-078 |